Affordable Access

Access to the full text

An overview of vaccine development for COVID-19

Authors
  • Shahcheraghi, Seyed H
  • Ayatollahi, Jamshid
  • Aljabali, Alaa AA
  • Shastri, Madhur D
  • Shukla, Shakti D
  • Chellappan, Dinesh K
  • Jha, Niraj K
  • Anand, Krishnan
  • Katari, Naresh K
  • Mehta, Meenu
  • Satija, Saurabh
  • Dureja, Harish
  • Mishra, Vijay
  • Almutary, Abdulmajeed G
  • Alnuqaydan, Abdullah M
  • Charbe, Nitin
  • Prasher, Parteek
  • Gupta, Gaurav
  • Dua, Kamal
  • Lotfi, Marzieh
  • And 2 more
Type
Published Article
Journal
Therapeutic Delivery
Publisher
"Future Science, LTD"
Publication Date
Feb 24, 2021
Identifiers
DOI: 10.4155/tde-2020-0129
PMID: 33624533
PMCID: PMC7923686
Source
PubMed Central
Keywords
Disciplines
  • Special Report
License
Green

Abstract

The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines – peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus – are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.

Report this publication

Statistics

Seen <100 times